Skip to main content

Advertisement

Table 3 Pharmacokinetic parameters following administration of the first dose of 150 mg or 2 mg/kg canakinumab

From: Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)

Patient Dose (mg) Cmax (μg/mL) Tmax (d) AUC0-∞ (μgd/mL) t1/2 (d) CL/F(L/d) Vz/F(L) CL/F/wt(L/d)/kg
1 34.8 NE NE NE NE NE NE NE
2 36.0 13.6 6.96 580 25.7 0.0621 2.3 0.0034
3 46.6 7.67 2 NE NE NE NE NE
4 48.0 NE NE NE NE NE NE NE
5 71.0 12.4 2 543 23.7 0.131 4.48 0.0037
6 150.0 16.3 7.05 647 22.9 0.232 7.67 0.0048
7 150.0 10.4 2.16 NE NE NE NE NE
  1. NE: : non-estimable
  2. Cmax, Maximum (peak) serum drug concentration after drug administration; Tmax, Time to reach peak or maximum concentration following drug administration; AUC0∞, Area under the concentration-time curve from time zero to infinity; t1/2, The elimination half-life associated with the terminal slope (λz) of a semi logarithmic concentration-time curve; CL/F, The apparent total clearance from serum; Vz/F, The apparent volume of distribution during terminal phase